hIVIG review. Spurlock and Prittie. 2011. JVECC. Flashcards

1
Q

What is the main immunoglobulin in hIVIG?

A

IgG (>90% intact)

trace amounts of IgA, IgM, CD4, CD8, human leukocyte antigen molecules

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

is hIVIG acidic or alkaline?

A

acidic
lower pH deters infectious agents and prevents aggregation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the half-life of hIVIG in dogs?

A

7-9 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the 5 mechanisms by which hIVIG causes immunosuppression?

A
  • blocks Fc receptors
  • reduces cytokine synthesis
  • inhibits complement
  • facilitates removal of pathogenic autoantibodies
  • mediates Fas-FasL binding
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what cells in the dog has human IgG been shown to effectively bind to

A

canine monocytes and lymphocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

explain the mechanism of action of hIVIG via Fc receptors

A

normally Fc receptors on cell membranes bind to antigen-antibody complexes which leads to antibody-mediated phagocytosis

binding of human IgG to the Fc receptors blocks this phagocytosis -> decreases tissue damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

how does hIVIG facilitate autoantibody removal

A

postulated to directly bind to abnormal host antibodies -> stimulate removal

does not work as well in companion animals –> interspecies antibodies bind poorly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How does hIVIG reduce tissue damage through the complement system

A

normally IgG-antigen complex binds to circulating complement -> initiates cascade, leading to apoptosis
hIVIG -> blocks this pathway by binding to C3 and C4 complement fragments –> cannot generate MAC –> limits tissue damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what mechanism of hIVIG is the presumed reason for its success in dermatologic conditions?

A

blockade of Fas-FasL complex formation -> inhibits keratinocyte apoptosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which of the 5 mechanisms of action of hIVIG is targeted for its use in IMHA

A

Fc receptor blockage -> happens immediately and may help stabilize patient until other immmunomodulatory drugs start to work

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the current evidence supporting hIVIG use in dogs with IMHA?

A
  • lack of evidence, randomized controled,blinded trial of 28 dogs did not show significant difference
  • current evidence cannot justify use

Whelan et al

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the current evidence supporting hIVIG use in dogs with ITP?

A

Bianco et al, Randomized, controlled, blinded
glucocorticoids + hIVIG vs. glucocorticoids alone
faster resolution of thrombocytopenia, and earlier discharge from hospital

results compare to Rosanzki et al study of glucocorticoids versus glucocorticoids + vincristine though
need vincristine vs hIVIG to justify use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the pathogenesis of myasthenia gravis?

A

immune-mediated neuromuscular disorder
autoantibody mediated destruction of acetylcholine receptors in the postsynaptic neuromuscular junction
-> weakness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

List the adverse effects of hIVIG

A
  • acute hypersensitivity/transfusion reactions
  • thromboembolism
  • renal failure
  • hypotension
  • aseptic meningitis
  • fluid overload
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the presumed underlying mechanism of transfusion reactions from hIVIG?

A

IgG aggregation and complement activation
type I hypersensitivity reactions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What implementations have reduced occurence of hypersensitivity reactions from hIVIG?

A
  • removal of aggregates
  • slow transfusion rates
  • hIVIG preparations with lower IgA levels
17
Q

What are the 4 mechanisms/properties by which hIVIG causes hypercoagulability in patients?

A
  • increased platelet numbers and platelet activation
  • contains prothrombotic factor Xa
  • hyperosmolarity
  • hyperviscosity
18
Q

How does hyperviscosity cause thromboembolic disease?

A

via impediment of capillary flow

19
Q

How does hIVIG primarily cause renal injury?

A

secondary to osmotic damage to the proximal tubules

20
Q

what component of hIVIG is implicated to cause renal injury?

A

sucrose - agent used to stabilize hIVIG preparations

alternative stabilizers are albumin, glucose, maltose, glycine, D-sorbitol

21
Q

How does an type III allergic reaction lead to renal injury?

A

allergen-IgG complex precipitaiton in renal tissues leads to inflammation via complement fixation -> glomerulonephritis develops

22
Q

Are larger or smaller donor pools of hIVIG saver for patient?

A

smaller donor pools -> the larger the donor poor the higher the risk of igG dimerization and subsequent complement activation -> leads to hypotensive events

23
Q

Does acidic or alkaline pH reduce the risk of IgG dimerization?

A

low pH (acidic)

24
Q

At what rate should hIVIG be started and what is the maximum rate for administration of hIVIG?

A

start at 0.1 mL/kg/min
maximum rate 0.08 mL/kg/,in

25
Q

How long until onset of Fc blockade after administering hIVIG?

A

3 days
rapid response in dogs has been reported within 24-48 hours

26
Q

List 6 conditions hIVIG has been previously evaluated for

A
  • IMHA
  • ITP
  • Evans Syndrome
  • Cutaneous autoimmune disease
  • MG
  • SARDS